2026 B2B Pharma Partnering Platform Benchmark

1IBHub vs. Legacy Pharma BD Networks & Partnering Conferences

Compare continuous digital partnering, conferences, research-consortium discovery, digital health innovation programs, enterprise intelligence, transaction advisory, ingredient sourcing and life-science procurement for pharma business development.

Comparison matrix

Feature / Metric1IBHubBePharmab2match / Health.techIN-PARTPipelinepharmaAllan Lloyds (Global Medical Affairs Summit)euroPLX (RauCon)CPhI (Informa Markets / cphi.com)PharmaVenturesPharmaVenue (pharmavenue.com)NSB Matchmaking (nsbmatchmaking.com)Catalyst Health (catalyst.health)Cortellis (Clarivate / cortellis.clarivate.com)ForesightRx (foresightrx.com)Pharma Synergy Conference (pharma-synergy-conference.com)Pharmaoffer (pharmaoffer.com)Scientist.com (scientist.com)
Pricing modelFlat €299 / year€1,500 – €5,000+ per event ticketEvent ticket + platform add-ons$10,000 – $50,000+ enterprise annualFree basic / project & success fees€3,500 per delegate ticket (2-day physical event)€1,100 – €1,700 per delegate per event (+ travel & hotel)€499 – €3,999 per pass (€15,000 – €70,000+ for exhibitors incl. travel/stand)Advisory retainers + transaction success commissions€1,199 – €1,899 per participant (+21% VAT & travel/hotel costs)Free BASE tier / PRO contact access granted on request; confirm current termsSponsored innovation programs and bespoke services; pricing on enquiryEnterprise intelligence subscriptions; current pricing available from ClarivatePharma retainers / curated-intelligence subscriptions + biotech success-based engagements; proposal-based terms2027 individual passes: Rx £1,745 / OTC £1,545 excl. VAT; travel and hotel extraBuyer sourcing free; supplier free/paid plans; trade-data Pro €199/mo for 3 months, then €249/moEnterprise procurement agreements; supplier entry/quoting free, buyer SaaS tariff not publicly verified
Brokerage / success fees0% brokerage fees0% (event cost only)0% (event cost only)0% (SaaS enterprise fee)Success & project commission fees0% (high ticket event cost only)0% (event registration fees only)0% (high exhibition & registration cost)Success commissions & percentage cuts on completed transactions0% (high event registration fee only)EU R&D partner-discovery model; brokerage terms not publicly specifiedProgram / service model; transaction-fee terms not publicly specifiedData subscription model; contract-specific fee terms require confirmationSuccess fee on deals or investment closed through introductions; rates and add-on fees depend on engagementEvent registration model; partnering included in pass, brokerage terms not explicitly verifiedPublished terms: no commission unless agreed otherwise in writing; escrow fees not verifiedSupplier transaction fee varies by request / marketplace partner; no universal percentage verified
Availability windowContinuous 365-day access2–3 day event sprints2–3 day conference sprints365-day deal room365-day directory & services2-day annual physical event (Berlin)Periodic 2-day meetings (3–4 times per year) + limited video windows3-day annual mega-exhibition + short pre-show app accessProject-based advisory mandates (6–12 month cycles)Periodic 2-day conference sprints + limited pre/post virtual meeting toolContinuous community directory and search across public European R&D sourcesPeriodic innovation challenges, pilot programs and scheduled matchmakingOngoing intelligence database access, including historical deals and current pipelinesOngoing curated intelligence, conference sourcing and project advisory; a 12-month pharma retainer is offeredSeparate two-day Rx and OTC physical events; platform opens three weeks before each eventYear-round ingredient, CDMO/CRO/CMO sourcing and trade-intelligence portalYear-round life-science sourcing, procurement and project workflows
Taxonomy precisionFull WHO ATC (1–5) & EPHMRA 2026 NFC (1–3)Generic keyword searchGeneral therapeutic tagsEarly-stage R&D keywordsBasic dosage / active form tagsNone (broad agenda topics: Medical Affairs, RWE, HEOR, GenAI)Basic general category dropdowns (Rx, OTC, Generics, Medical Devices)Broad industry tags (APIs, FDF, CDMO, Machinery)None (manual target research & advisory screening)Basic general product category and company profile dropdownsHealthcare, rehabilitation and EU R&D ecosystem categories (Horizon Europe / Interreg)Digital health, healthtech and clinical innovation themesClinical indication, mechanism-of-action (MoA), pipeline and deal research classificationsAI-assisted asset matching and consultant screening; self-serve WHO ATC / NFC filters not established in reviewed sourcesCompany and portfolio profiles; full self-serve WHO ATC / NFC filtering not establishedIngredient names / CAS, qualification filters; drug-product service categories include dosage formsScientific categories and provider matching across discovery, clinical, manufacturing and commercial services
IP privacy & anonymityBlind Profiles (double opt-in reveal)Public registration listOpen participant directoryNon-confidential summariesDirect company listingPublic attendee directory & speed networkingPre-scheduled meeting directory & delegate listPublic exhibitor directory & attendee listManual non-confidential teasers (NCDs) distributed by advisorsOpen delegate directory & pre-scheduled meeting agendaLimited organization details on BASE; full registered-partner contacts on PROChallenge submissions and pitch programs; disclosure varies by programIntelligence from reported deals, patents, regulatory and clinical information; not anonymous marketplace listingsAdvisor-managed confidential information and introductions; retainer page also advertises a client dashboardAuthorized-email partnering access and detailed delegate profiles; anonymous asset workflow not establishedPublic supplier profiles; quote form states confidential sharing with verified suppliersClient–supplier contracting / MSAs and published data-security controls; not a public Blind Profile model
Market focusCommercial assets (Generics, Biosimilars, VAPs, Rx/OTC) & CDMO/CRO servicesLatAm & EU generic / VAP commercial assetsRegional digital health & medtech clustersEarly-stage university tech transfer & Big Pharma R&DCommercial generics, dossiers & distribution dealsHigh-level Medical Affairs strategy, MSL leadership, RWE & scientific communicationsCommercial licensing, Generics, VAPs, OTC/Rx assets & CDMO/supply dealsGlobal pharmaceutical supply chain, APIs, finished dosage licensing, CDMO/CROHigh-ticket M&A, divestments, early-to-commercial licensing and valuationsIn-/out-licensing, Generics, VAPs, OTC/Rx assets and distribution for small-to-mid pharmaEU-funded research consortia, rehabilitation and academic R&D partnershipsDigital health innovation, health-system pilot programs and startup / investor ecosystemsCompetitive intelligence, clinical trials, R&D deal analytics and valuation benchmarkingBiotech out-licensing, pharma pipeline sourcing, BD readiness and early health economic modelingRx licensing, Generics, value-added medicines, Biosimilars; OTC and Consumer Health distributionAPIs, excipients, intermediates, drug-substance and drug-product contract servicesLife-science services and products across discovery through commercialization, including CRO/CDMO sourcing
Dual-sector coverageHuman & Animal HealthHuman Health primarilyHuman Health & TechHuman Health & BiotechHuman Health primarilyHuman Health primarily (large-cap & mid-sized pharma)Human Health primarilyHuman Health primarily (with broad veterinary supply)Human Health & Life Sciences (Biotech, Pharma, CDMO/CRO)Human Health primarilyHuman Healthcare & Rehabilitation R&DHuman Digital Healthcare & Health TechHuman Health & Life Sciences (Biopharma & Medtech)Biopharma / Human Health emphasis; equivalent Animal Health coverage not establishedHuman Rx / OTC and Consumer Health emphasis; equivalent Animal Health coverage not establishedPharmaceutical ingredient and manufacturing supply; equivalent dual-sector coverage not establishedPharma, biotech and academic research; equivalent Human / Animal Health marketplace coverage not established

Third-party information reflects publicly available indications; ForesightRx, Pharma Synergy, Pharmaoffer and Scientist.com were reviewed on 28 October 2026. Terms may vary by event, package or region. Please verify current terms with each provider. All trademarks belong to their respective owners. The additional benchmarks below use linked provider sources. Unpublished prices, fee policies and disclosure rules are marked for confirmation rather than assumed.

Platform-by-platform breakdown

BePharma

bepharma.org

Event-driven partnering for generic and value-added commercial assets, strongest in Latin America and Europe. Value is concentrated in a short event window, with ticket costs per attendee.

Best if you want in-person meetings at a specific regional event.

b2match Health & Health.tech

b2match.com · health.tech

Meeting-scheduling platforms attached to conferences and regional clusters, typically with open participant directories and broad therapeutic tags.

Best for conference attendees in digital health and medtech.

IN-PART

inpart.io

Enterprise-priced deal room connecting universities and R&D teams around early-stage technologies via non-confidential summaries.

Best for early-stage academic tech-transfer scouting with an enterprise budget.

Pipelinepharma

pipelinepharma.com

Directory and marketplace for commercial generics, dossiers and distribution, with project and success-based fees on transactions.

Best if you prefer a free entry tier and accept success fees.

Allan Lloyds (Global Medical Affairs Summit)

mdaffairs.com

A 2-day annual physical congress in Berlin for Medical Affairs leadership, MSL teams, RWE/HEOR and scientific communications, with an agenda-led programme, a public attendee directory and speed networking. Deal sourcing is not structured around asset-level criteria — the value sits in a single high-ticket networking window each year.

Best for Medical Affairs executives seeking in-person strategy networking in Berlin, not for asset-level deal sourcing.

euroPLX (RauCon)

europlx.com

Periodic 2-day partnering meetings held three to four times per year, built around pre-scheduled bilateral meetings with a delegate directory and limited video windows. Classification relies on basic general category dropdowns (Rx, OTC, Generics, Medical Devices), with per-event delegate fees plus travel and hotel costs.

Best for commercial licensing teams who prefer recurring in-person meeting rounds on a fixed event calendar.

CPhI (Informa Markets)

cphi.com

The global pharmaceutical supply-chain mega-exhibition: three days each year plus a short pre-show app window, with broad industry tags (APIs, FDF, CDMO, Machinery), public exhibitor and attendee directories, and per-pass fees ranging from €499 to €3,999 — with exhibiting companies paying €15,000–€70,000+ once travel and stand costs are included. Coverage spans APIs, finished dosage licensing and CDMO/CRO, but access is concentrated in a single annual window with no asset-level taxonomy.

Best for supply-chain and sourcing teams who plan an annual exhibition visit.

PharmaVentures

pharmaventures.com

A specialist advisory firm for high-ticket M&A, divestments, early-to-commercial licensing and valuations, working on project mandates that typically run 6–12 months. Deal flow is screened manually rather than via taxonomy, and counterparties are approached with advisor-distributed non-confidential teasers (NCDs). Compensation comes from retainers plus success commissions — commonly 3–5%+ of deal value.

Best for large transactions where a retained advisor and percentage-based success fee fit the deal size.

1IBHub

1ibhub.com

A continuous 365-day digital partnering engine for products and services across human and animal health. Blind Profiles protect identity until double opt-in; full WHO ATC 1–5 and EPHMRA NFC 1–3 filters isolate exact fits; flat €299/year with zero brokerage fees.

Best for BD teams sourcing or out-licensing commercial assets and services year-round.

1IBHub vs. Boutique Regional Partnering Conferences (PharmaVenue)

PharmaVenue is a recognized boutique partnering event series designed to facilitate speed-dating style 1-on-1 meetings for small-to-mid-sized pharmaceutical companies across Europe and Latin America.

While PharmaVenue offers focused networking for attending decision-makers, relying exclusively on event-based meeting calendars presents clear operational limitations:

  • Year-Round Marketplace vs. 2-Day Events: Rather than waiting for periodic physical conferences to pitch or source portfolios, 1IBHub keeps your deal pipeline open 365 days a year.
  • Radical Price Efficiency: A single delegate pass at PharmaVenue costs €1,199 to €1,899 (plus travel and hotel expenses). 1IBHub gives your entire BD workflow continuous, 365-day platform access for a flat €299/year.
  • Precision Sourcing Taxonomies: PharmaVenue relies on general company profile summaries. 1IBHub integrates full WHO ATC (Levels 1–5) active ingredient codes and EPHMRA 2026 NFC (Levels 1–3) dosage classifications for instant, hyper-targeted asset screening.
  • Confidential Market Testing: Test demand for sensitive portfolios without revealing company identity using 1IBHub's anonymous Blind Profiles before approving double opt-in contact reveals.

1IBHub vs. EU Grant & Research Consortia Platforms (NSB Matchmaking)

NSB Matchmaking, developed within the RehAllianCE Interreg consortium, connects European healthcare and rehabilitation organizations seeking research partners. Its community directory and public European R&D search support collaboration around programs such as Horizon Europe and Interreg.

Its emphasis is research collaboration and publicly funded consortia; 1IBHub offers a different workflow for commercial pharmaceutical assets and services:

  • Commercial Sourcing vs. Academic Grants: 1IBHub supports commercial in-/out-licensing of Generics, Biosimilars, VAPs and Rx/OTC assets, alongside CDMO/CRO services. NSB emphasizes healthcare and rehabilitation research partnerships and grant-oriented collaboration.
  • Standardized Pharma Taxonomies: 1IBHub offers WHO ATC Levels 1–5 therapeutic classification and EPHMRA 2026 NFC Levels 1–3 dosage classifications for product screening by therapeutic area and formulation.
  • Confidential Commercial Partnering: Blind Profiles let 1IBHub members test interest without publicly revealing company identity. Contact requests follow double opt-in before identities are revealed and direct Chat opens; confidential information should be shared only when appropriate.

Sources: NSB platform and BASE / PRO tiers

1IBHub vs. Digital Health Innovation Ecosystems (Catalyst Health)

Catalyst @ Health 2.0 works with healthcare organizations, investors and digital health innovators through innovation challenges, ecosystem development, pilot programs, market intelligence and professional matchmaking.

Catalyst's digital health innovation programs and 1IBHub's commercial pharma marketplace address different partnering needs:

  • Pharmaceutical Assets & Services vs. Digital Health Programs: 1IBHub supports pharmaceutical assets, ready-to-license dossiers, APIs, finished dosage forms and CDMO/CRO services across Human and Animal Health. Catalyst emphasizes digital health innovation and adoption, including pilot and ecosystem programs.
  • Continuous 365-Day Marketplace: Rather than organizing sourcing around a particular challenge or pitch session, 1IBHub provides year-round listing, filtering, matching and contact requests for a flat €299/year.
  • Zero Brokerage Fees: After an approved contact request or mutual match, members connect directly in Chat to discuss their licensing and service terms. 1IBHub charges no brokerage or success commission; counterparties remain responsible for their agreements.

Sources: Catalyst @ Health 2.0 · Innovation challenges · Programs and matchmaking services

1IBHub vs. Enterprise Retrospective Intelligence Databases (Cortellis / Clarivate)

Clarivate's Cortellis is a suite of life-sciences intelligence solutions covering deals, competitive landscapes, clinical trials, discovery and regulatory information. Cortellis Deals Intelligence supports partner identification, deal benchmarking, due diligence and negotiations using reported transactions and pipeline data.

The distinction is between an intelligence-led research workflow and an active marketplace for commercial partnering. These approaches can complement each other:

  • Active Marketplace vs. Intelligence Research: Cortellis helps teams identify potential partners and analyze deals and pipelines. 1IBHub lets members publish current commercial opportunities, filter assets and services, and request contact directly. Intelligence-based partner identification is not the same workflow as a member-posted marketplace.
  • Transparent Membership vs. Quote-Based Subscriptions: 1IBHub costs a flat €299/year with zero brokerage fees. Cortellis pricing depends on the subscribed products and contract; the official sources reviewed do not substantiate a universal $50,000–$100,000+ annual price range. Request a current quote from Clarivate.
  • Direct Peer-to-Peer Discussions: 1IBHub transitions approved contact requests and mutual matches into direct Chat for document exchange and negotiations. Members arrange any calls themselves; the platform does not provide automatic 15-minute introductory calls or execute transactions.
  • Anonymous Market Validation: Alongside research on reported deals and pipelines, teams can use 1IBHub Blind Profiles to test demand for their own commercial opportunities. Double opt-in contact requests protect company identity until approval.

Sources: Cortellis intelligence portfolio · Cortellis Deals Intelligence and Analytics

1IBHub vs. Tech-Enabled Brokerage & Advisory (ForesightRx)

ForesightRx, a division of MarksMan Healthcare, combines AI-assisted asset matching, conference-sourced intelligence and transaction advisory to connect biotech out-licensors with pharma buyers. Its scientific services include asset positioning, BD readiness, publications and early health economic modeling. These services can help teams that want hands-on representation rather than only a marketplace.

ForesightRx describes one curated-intelligence track with the statement ‘Neither of them logs into our system — that’s the point.’ However, its pharma BD retainer page also advertises a dedicated dashboard, pipeline tracking and an AI research copilot. Access therefore depends on the engagement: a blanket claim that all clients are excluded from the platform would be misleading. Compare the workflows and confirm current contract terms:

  • Self-Service Control vs. Managed Introductions: 1IBHub members search, filter, publish and request connections on their own timeline; an approved contact request or mutual match opens direct Chat. ForesightRx emphasizes curated shortlists, outreach, CDA facilitation and deal support. Reviewed sources do not establish that every NDA or document exchange must pass through its consultants.
  • Flat Membership vs. Retainers and Success Fees: ForesightRx describes pharma retainers or intelligence subscriptions and biotech fees tied to deals or investments closed through its introductions. Some service packages also describe fixed-fee add-ons; confirm the scope and fee basis in a proposal. 1IBHub charges a flat €299/year and 0% brokerage or success fees; members remain responsible for their contracts and any separate professional advice.
  • Commercial Asset Screening: 1IBHub supports commercial assets such as Generics, Biosimilars, VAPs and Rx/OTC products, as well as CDMO/CRO and other services across Human and Animal Health. Product listings can be screened using WHO ATC Levels 1–5 and EPHMRA 2026 NFC Levels 1–3. The reviewed ForesightRx sources emphasize biotech pipeline sourcing and advisory; they do not establish equivalent self-serve ATC/NFC screening or that commercial assets are excluded.
  • Member-Posted Blind Profiles: 1IBHub lets members publish anonymous Blind Profiles and approve contact requests before company identity is revealed through double opt-in. ForesightRx describes advisor-managed confidentiality and targeted introductions. These are different disclosure workflows, not evidence that an advisor cannot protect confidential information.

Sources: ForesightRx positioning and engagement tracks · Biotech partnering and fee model · Pharma BD retainer and dashboard access

1IBHub vs. Physical BD&L Partnering Conferences (Pharma Synergy)

Pharma Synergy combines pre-arranged one-to-one meetings with a content-driven conference program for pharmaceutical business development and licensing professionals. The organizer currently advertises separate two-day 2027 editions: Rx in London on 4–5 February and OTC in Paris on 23–24 September. Face-to-face meetings can complement ongoing digital sourcing.

Compare the event's focused networking opportunity with year-round self-service partnering, without assuming that an event ends all follow-up or guarantees a particular return on investment:

  • Year-Round Momentum Alongside Event Meetings: 1IBHub provides continuous 365-day listing, search and contact requests before and after a conference. Pharma Synergy's FAQ describes partnering access starting three weeks before an event; the reviewed sources do not establish a universal post-event cutoff or a 30-minute meeting duration.
  • Transparent Membership vs. Per-Delegate Event Costs: Official 2027 individual passes are £1,745 for Rx and £1,545 for OTC, excluding VAT; GBP is the base currency. Travel and accommodation add to the budget. 1IBHub membership is €299/year with 0% brokerage fees. These are different products and currencies—not a guaranteed ROI calculation or a claim that one membership covers an entire team.
  • Product-Level Taxonomy Screening: 1IBHub product listings support WHO ATC Levels 1–5 and EPHMRA 2026 NFC Levels 1–3 filters for therapeutic and dosage-form classification. Pharma Synergy describes detailed company profiles and portfolio interests; equivalent full self-serve ATC/NFC filtering is not established by the reviewed sources.
  • Different Disclosure Workflows: Pharma Synergy limits its partnering platform to authorized email addresses and lets delegates choose which meetings to accept. This is not evidence of absent confidentiality. 1IBHub offers member-posted anonymous Blind Profiles, with identity revealed after double opt-in contact approval; this does not replace NDAs or guarantee IP protection.

Sources: Pharma Synergy Rx program and dates · Pharma Synergy OTC program and dates · Rx individual ticket · OTC individual ticket · Partnering access FAQ · Registration terms

1IBHub vs. Bulk API & Raw Material Catalogs (Pharmaoffer)

Pharmaoffer connects pharmaceutical buyers with ingredient suppliers and contract service providers. Its directories cover APIs, excipients and intermediates, plus drug-substance CDMO/CRO and drug-product CMO services. It also offers customs-based trade intelligence to support sourcing decisions.

Ingredient procurement and commercial licensing are different workflows, but manufacturing-service sourcing overlaps. Compare the intended task rather than assuming the platform cannot serve business development:

  • Commercial Licensing Alongside Supplier Procurement: Pharmaoffer emphasizes supplier discovery, quote requests and direct contracting, including services for finished drug products. 1IBHub additionally supports member-posted commercial licensing opportunities, regional-rights discussions and company or product divestments, alongside APIs and services across Human and Animal Health.
  • Different Screening Taxonomies: Pharmaoffer supports ingredient-name and CAS search, qualification/document filters and drug-product service categories such as oral solids and sterile injectables. 1IBHub product listings use complete WHO ATC Levels 1–5 and EPHMRA 2026 NFC Levels 1–3 classifications. The sources reviewed do not establish equivalent complete ATC/NFC filters on Pharmaoffer; they do not justify saying it has no dosage-form categories.
  • Blind Profiles vs. Supplier Visibility: Pharmaoffer's supplier profiles are publicly discoverable, while its quote form states requests are handled confidentially and shared with verified suppliers. 1IBHub's anonymous Blind Profiles use double opt-in before company identity is revealed. These are distinct disclosure workflows, not proof that procurement requests lack confidentiality.
  • Compare the Actual Fee Models: Pharmaoffer buyer sourcing is free, suppliers can have free or paid plans, and its published terms say no commission is charged unless agreed otherwise in writing. Trade-data Pro is separately advertised at €199/month for the first three months, then €249/month, or €2,490/year. Supplier tariffs and escrow fees are not verified here. 1IBHub membership is €299/year with 0% brokerage fees; do not assume a standard Pharmaoffer transaction margin.

Sources: Buyer sourcing workflow · Supplier visibility and sourcing · Drug-substance and drug-product services · Trade-data subscriptions · Commission terms · Quote-request confidentiality

1IBHub vs. Life-Science R&D Procurement Marketplaces (Scientist.com)

Scientist.com is a life-science procurement platform combining provider discovery, guided buying, contracting, compliance and project workflows. Its current platform description covers discovery, preclinical research, clinical work, manufacturing and commercial operations—not only early-stage laboratory research. Standardized agreements and its COMPLi compliance framework can support organizational purchasing requirements.

The useful distinction is procurement orchestration versus member-led commercial partnering, with overlapping service categories rather than mutually exclusive markets:

  • Commercial Partnering vs. Procurement Orchestration: Scientist.com helps teams source and manage providers, proposals, approvals and spend across the drug-development lifecycle. 1IBHub lets members publish licensing, product or company divestment and service opportunities across Human and Animal Health, then request direct contact. Do not assume Scientist.com excludes manufacturing or commercial services.
  • Direct Discussions vs. Organizational Buying Workflows: An approved contact request or mutual match opens direct Chat on 1IBHub, where members discuss terms and exchange documents. Scientist.com provides procurement, contracting and compliance workflows, which may be useful where corporate controls are required. Members arrange any calls themselves; 1IBHub does not automatically book 15-minute introductions or certify every decision-maker.
  • Flat Membership vs. Request-Specific Supplier Fees: Scientist.com's official supplier FAQ states that registration and quoting are free, while transaction fees and payment terms vary by request and marketplace partner. A universal buyer SaaS price or supplier commission percentage is not verified. SciPay early-payment charges are separate from marketplace transaction fees. 1IBHub costs €299/year with no brokerage or success commission.
  • Taxonomy and Confidentiality for Different Tasks: Scientist.com describes scientific-category matching, contracting and data-security controls. The reviewed sources do not establish equivalent complete WHO ATC/NFC product filters or a member-posted anonymous asset marketplace. 1IBHub provides ATC Levels 1–5 and EPHMRA 2026 NFC Levels 1–3 for product listings, with Blind Profiles and double opt-in disclosure; this is not a replacement for procurement governance, NDAs or due diligence.

Sources: Platform scope and scientific categories · Supplier model and SciPay terms · Supplier fees and agreements FAQ · COMPLi compliance framework · Published data-security controls

Source deals all year, not just for three days

Flat €299 per year, zero brokerage fees, Blind Profiles and full ATC/NFC precision.

Join 1IBHub